Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Sep 11, 2023 12:00pm
130 Views
Post# 35629490

RE:RE:RE:RE:RE:RE:New article in La Presse this morning

RE:RE:RE:RE:RE:RE:New article in La Presse this morning Sorry SPCEO1, but Philippe's comment jfm shared from the French paper makes zero sense within the context of the assumptions you're making.  Maybe there's a language barrier?  I have to assume Philippe would have chosen very different words if they had been in blackout and not reference buying shares "this week" and then go on to specifically identify the end of the quarter and the release of financial results as a current blackout period.  That is a normal blackout period for most companies, and it sounds like an excuse.  And yet, it still doesn't explain why those expired options haven't been dealth with.  I would very much like to know the status of those options.  On the flip side, maybe this is Philippe's horrible way of communicating that they have been in blackout for 9 full months due to something we don't know about and that very thing is so material that it's prevented them from doing anything.  I just can't believe that to be the case.  These guys still do not have my trust, but I thought Philippe's comments were fairly clear.  If he's trying to hint at something here, it didn't come through for me on his specific statement.  

'Theratechnologies executives did not buy shares of the company this week because they could not do so due to regulations. “We are often in blackout [period of prohibition to conclude transactions], and this is the case at the moment between the end of the quarter and the release of results at the end of September,” says Philippe Dubuc.'

Do you beleive they've been in blackout this entire year?  If so, what realistically would be cause for such extreme caution on any insider transactions?
<< Previous
Bullboard Posts
Next >>